- Investopedia•3 hours ago
Bavencio, the first and only approved drug for MCC treatment, is under study for multiple other cancers.
- Bloomberg•5 hours ago
Pfizer and Merck KGaA’s cancer immunotherapy won approval from U.S. regulators for patients with a rare form of skin cancer, and the companies plan to sell the drug for $13,000 a month. Merck KgaA CEO ...
- PR Newswire•15 hours ago
FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
DARMSTADT, Germany and NEW YORK, March 24, 2017 /PRNewswire/ -- Not intended for UK-based media Only FDA-approved treatment for metastatic Merkel cell carcinoma, a rare and aggressive skin cancer ...
PFE : Summary for Pfizer, Inc. - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||34.21 x 1000|
|Ask||34.49 x 400|
|Day's Range||34.23 - 34.56|
|52 Week Range||29.41 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.23|
|Dividend & Yield||1.28 (3.71%)|
|1y Target Est||N/A|